What the Current U.S. Rules Actually Cover
The Treasury Department's Outbound Investment Security Program was established following an executive order issued in August 2023.
The program applies to certain investments by U.S. persons involving entities connected with countries of concern and operating in specified national-security technology areas.
Treasury identifies the People's Republic of China, along with Hong Kong and Macau, as a country of concern under the program.
The rules took effect on January 2, 2025.
They are designed to prohibit certain transactions and require notification for others, depending on the type of investment and technology involved.
Three Technology Areas Are at the Center
The current framework focuses on three broad areas.
1. Semiconductors and Microelectronics
The rules cover certain investments involving advanced semiconductor and microelectronics technologies and products.
These areas are considered strategically important because of their applications in advanced computing, military systems and other sensitive technologies.
2. Quantum Information Technologies
Quantum computing and related technologies are another area covered by the program.
The rules target specified activities involving quantum information technologies because of their potential national-security applications.
3. Artificial Intelligence
Certain AI systems and related activities are also covered.
The Treasury framework focuses on specified AI technologies and applications rather than treating every AI-related investment as automatically restricted.
Where Do Pharmaceutical Deals Fit?
This is where the distinction becomes important.
The current Treasury Outbound Investment Security Program does not list pharmaceuticals as one of its three technology categories.
That does not mean every pharmaceutical transaction involving China is automatically outside all U.S. laws or national-security controls. Other U.S. laws, sanctions, export controls and regulatory requirements can apply depending on the companies, technology, transaction and circumstances.
However, the existing Treasury outbound-investment framework itself is specifically structured around the three technology areas identified above.
Treasury also says the rules are narrowly targeted rather than being a blanket prohibition on investment in countries of concern.
Licensing and Investment Are Not the Same Thing
Another important detail is the difference between a licensing agreement and an investment.
Treasury's FAQ explains that covered transactions under the current program can include certain equity acquisitions, contingent equity interests, debt financing with specified rights, greenfield investments, corporate expansions, joint ventures and certain limited-partner investments.
The Treasury FAQ also addresses technology licensing, consulting and procurement contracts, explaining that activities that do not meet the program's definition of a covered transaction are generally outside the program, unless they are undertaken to evade or avoid the rules.
That distinction matters when discussing pharmaceutical licensing arrangements.
A licensing deal does not automatically become a restricted outbound investment simply because it involves a Chinese company.
Why the Pharma Question Matters
The pharmaceutical industry has become an important part of the broader U.S.-China economic relationship.
Drugmakers can work across borders through licensing agreements, research partnerships, manufacturing arrangements, investments and other commercial relationships.
At the same time, governments increasingly examine whether certain technologies, biological capabilities or supply chains could create national-security concerns.
That makes the exact wording and scope of any future U.S. rules particularly important for pharmaceutical companies.
For businesses, the difference between a broad restriction and a narrowly targeted framework could have major implications for how they structure partnerships with Chinese companies.
What Has Actually Been Confirmed?
As of the latest official information reviewed for this article, the U.S. Treasury has not publicly announced a final pharmaceutical-specific outbound investment framework that broadly changes the treatment of China-related pharma licensing deals.
The existing Treasury program remains focused on semiconductors and microelectronics, quantum information technologies, and artificial intelligence.
Treasury's own FAQ also says that the current rules do not prohibit all investment activity in countries of concern. Instead, they target certain types of investments connected with specified sensitive technologies and products.
That means claims about a new pharma licensing policy should be treated carefully until an official rule, announcement or regulatory document is published.
The Bigger Picture for U.S.-China Business
The current rules show how Washington is trying to balance international investment with national-security concerns.
Rather than applying the same restrictions to every industry, the Treasury program identifies specific technologies considered particularly sensitive.
The pharmaceutical sector could still face scrutiny under other U.S. laws or future policy changes, particularly where activities involve sensitive technologies, biological capabilities or other national-security considerations.
For companies operating between the United States and China, the practical question will therefore be which specific transaction is being considered, which entities are involved and which U.S. rules apply.
What to Watch Next
For now, the official record provides a clearer picture than speculation about a potential new pharma framework.
The Treasury's current outbound investment rules remain in force, and companies involved in China-related transactions must continue to assess whether their activities fall within the existing requirements.
If Washington introduces a new pharmaceutical-specific rule, the most important details will be its definition of covered transactions, the companies and technologies affected, and whether licensing arrangements are included or excluded.
Until such an announcement is made, it is more accurate to describe a potential pharma framework as a policy issue under consideration rather than an established U.S. government rule.